logo
Plus   Neg
Share
Email

China Ming Yang Wind Power Posts Loss In Q4 - Quick Facts

China Ming Yang Wind Power Group Ltd. (MY) reported fourth-quarter loss attributable to shareholders of RMB 117.95 million, or $18.74 million, versus a profit of RMB 228.93 million last year. Loss per share was RMB 0.96, or $0.15, versus earnings per share of RMB 1.83 in the same quarter last year.

Revenue fell to RMB 808.3 million, or $128.43 million, from RMB 1.71 billion in the prior-year quarter.

The lower revenues was primarily due to the delayed EPC projects representing an equivalent wind power project output of 196.5MW, or 131 units of 1.5MW WTGs; the delays in installation and commission of 1.5MW WTGs of certain wind farm projects representing an equivalent wind power project output of 40.5MW, or 27 units, primarily caused by adverse weather conditions; and slower growth in the wind industry in China in 2011.

Chuanwei Zhang, Chairman and CEO of Ming Yang, commented, "...Against this industrial slow-down, I am pleased to report that Ming Yang has continued to see sustained demand through the full year 2011, and has also been able to reach its targeted gross margin on an annual basis, despite the previously announced delays in revenue recognition and overall market softness impacting performance and results in the fourth quarter."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT